Document -
AbbVie Receives CHMP Positive Opinion for SKYRIZI™ ▼ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis in adults
CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission1-3
-
License:
All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
- File format: .docx